Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type | Zendy

Al Dhafiri Mahdi | Zendy; Sicre de Fontbrune Flore | Zendy; Marinho Eduardo | Zendy; Deschamps Lydia | Zendy; DiLucca Julie | Zendy; Crickx Beatrice | Zendy; Descamps Vincent | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type

Author(s) -

Al Dhafiri Mahdi,

Sicre de Fontbrune Flore,

Marinho Eduardo,

Deschamps Lydia,

DiLucca Julie,

Crickx Beatrice,

Descamps Vincent

Publication year - 2019

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.2137

Subject(s) - medicine , lenalidomide , chop , lymphoma , refractory (planetary science) , radiation therapy , diffuse large b cell lymphoma , oncology , dermatology , multiple myeloma , physics , astrobiology

Key Clinical Message The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research